Lupin Ltd has secured exclusive rights in India for Bofanglutide, a novel fortnightly GLP-1 receptor agonist, through a licensing agreement with China's Gan & Lee Pharmaceuticals. This strategic move bolsters Lupin's diabetes and obesity treatment portfolio, offering a convenient and effective option for patients amidst a growing metabolic health challenge in India.